Introduction
============

Schizophrenia is a common mental disorder effected by the mutual influence of multiple genetic[@b1-ndt-10-645] and environmental factors,[@b2-ndt-10-645] and its heritability is up to 80%.[@b3-ndt-10-645] In order to clarify the pathological mechanisms, many studies have been carried out over the years, but a consistent conclusion has still not been achieved. To date, dysregulation of dopaminergic neurotransmission has been implicated in the pathogenesis of schizophrenia.[@b4-ndt-10-645],[@b5-ndt-10-645] The reduction of prefrontal cortical dopamine neurotransmission likely leads to schizophrenia.[@b6-ndt-10-645]

Dopamine is an important endogenous neurotransmitter that plays a significant role in modulating cognitive, mood, and motor functions of the brain.[@b7-ndt-10-645] It plays a regulatory function by binding to the dopamine receptors of the postsynaptic membrane. The sequence of the dopamine D~1~ receptor gene (*DRD1*) has been identified and mapped to chromosome 5q35.1.[@b8-ndt-10-645] Linkage between *DRD1* and schizophrenia has been reported in Chinese,[@b9-ndt-10-645] American,[@b10-ndt-10-645] and Portuguese populations.[@b11-ndt-10-645] As we all know, a remarkable symptom of schizophrenia patients is cognitive dysfunction (such as attention-deficit and memory disorders).[@b6-ndt-10-645],[@b12-ndt-10-645] Interestingly, an optimal amount of *DRD1* stimulation is essential in maintaining normal prefrontal cognitive function.[@b13-ndt-10-645],[@b14-ndt-10-645] Studies[@b15-ndt-10-645]--[@b17-ndt-10-645] show that deficits in *DRD1* transmission are associated with cognitive and negative symptoms of schizophrenia, and there is a significant decrease in *DRD1* expression in the basal ganglia of schizophrenic patients. *DRD1* gene polymorphisms likely play a role in the occurrence of schizophrenia by affecting the expression of the D~1~ receptor. The rs1799914 genetic polymorphism is associated with schizophrenia in a Korean population.[@b18-ndt-10-645] A study of five single-nucleotide polymorphisms (SNPs; rs11746641, rs11749676, rs251937, rs12518222, rs4867798) has reported that rs11746641 and rs11749676 are associated with schizophrenia in males, and the haplotype T-A-T-C-T can reduce the risk of schizophrenia.[@b19-ndt-10-645] The genetic polymorphism of rs4532 is likely associated with deficits in executive function and performance on the Wisconsin Card Sorting Test.[@b6-ndt-10-645] However, no association between rs4532 and schizophrenia has been reported,[@b20-ndt-10-645],[@b21-ndt-10-645] and a consistent conclusion has still not been achieved.

Many previous studies analyzed a few loci (one to five SNPs) or selected several tag SNPs as a substitute for the entire gene region. However, the limitation of several loci could not completely pinpoint the true susceptible SNPs, owing to the weak linkage disequilibrium in the *DRD1* gene. Most likely, the basis of inconsistent results was due to this factor. We analyzed eleven SNPs in the 5′-flanking and untranslated regions of the *DRD1* gene by deoxyribonucleic acid (DNA) sequencing, and carried out a case-control study between 173 paranoid schizophrenia patients and 213 unrelated healthy controls.

Materials and methods
=====================

Samples
-------

Blood samples from 213 healthy, unrelated, northern Han Chinese volunteers (112 males and 101 females, average age 40.1±14.7 years) were provided by China Medical University's Department of Blood Serum in the School of Forensic Medicine. Questionnaires confirmed there was no history of mental disease going back three generations. Blood samples from 173 northern Han Chinese patients with paranoid schizophrenia (88 males and 85 females, average age 43.7±13.5 years) were provided by the Third People's Hospital of Liaoning Province. Each patient was diagnosed by at least two senior psychiatrists. Diagnostic criteria for paranoid schizophrenia were in line with the *Diagnostic and Statistical Manual of Mental Disorders* (fourth edition)[@b22-ndt-10-645] on the basis of unstructured interviews and information from medical records. The study protocol and process was assessed and approved by the ethics committee at China Medical University. In the present study, all subjects signed the informed consent form.

Selection of polymorphic loci
-----------------------------

Polymerase chain reaction (PCR) was used to amplify *DRD1* fragment length, including 5′-flanking and untranslated regions. The nucleotide position of one fragment amplified was from --3,052 to --1,483 (primer sequence \[forward\] -- ctgatatggtgcatggctgtt, \[reverse\] -- acctgcgttgtctccaagtgt). The nucleotide position of the other fragment amplified was from --1,505 to +100 (primer sequence \[forward\] -- ggacacttggagacaacgcag, \[reverse\] -- atgagcagcgacaggaaacag). The amplified fragment included 45 SNP loci that had been reported in the National Center for Biotechnology Information database ([www.ncbi.nlm.nih.gov/gene/](http://www.ncbi.nlm.nih.gov/gene/)),[@b39-ndt-10-645] and were genotyped by DNA sequencing. The frequencies of the SNP loci (\>1%) were screened. Eleven polymorphic loci were detected in the northern Han Chinese population, including one newly discovered SNP loci: ss492961114/rs201089398 in the 5′ regulatory region. A schematic diagram for *DRD1* is shown in [Figure 1](#f1-ndt-10-645){ref-type="fig"}.

Genotyping
----------

Genomic DNA was extracted by the traditional phenol-chloroform method and quantified with ultraviolet (UV) spectrophotometry. An ABI9700 amplifier (Applied Biosystems, Foster City, CA, USA) was used to amplify the target band. Beijing Genomics Institute (ABI3730XL) was commissioned for sequencing.

Statistical analysis
--------------------

SPSS 18.0 software (IBM, Armonk, NY, USA) was used to calculate genotype frequency and allele frequency, and Haploview 4.1 software (Broad Institute, Cambridge, MA, USA) was used for the Hardy--Weinberg equilibrium test, the confirmation of haplotypes, and analysis of intergroup differences. The *χ*^2^ test was used to measure the association of paranoid schizophrenic risk with *DRD1* genotypes, alleles, and haplotypes between control and disease groups. Unconditional logistic regression models were used to obtain maximum-likelihood estimates of odds ratios (ORs) and their 95% confidence intervals (CIs) between each locus and the presence of paranoid schizophrenia. The Bonferroni correction was used in multiple testing, and *P*-values were divided by the total number of loci or haplotypes.

Results
=======

Haploview 4.1 was used to test genotype fitness for the control and paranoid schizophrenic groups. The results showed that the distribution of no genotype frequencies at all loci deviated from the Hardy--Weinberg equilibrium in either group or in the male and female subgroups (*P*\>0.05). Results of linkage analysis for control and disease groups are shown in [Figure 2](#f2-ndt-10-645){ref-type="fig"}.

Genotype and allele frequencies of eleven SNP loci in *DRD1* are shown in [Table 1](#t1-ndt-10-645){ref-type="table"}. The *χ*^2^ test was used to measure the association of paranoid schizophrenic risk with *DRD1* genotypes. Among them, the genotype distribution of rs5326 was statistically different between paranoid schizophrenia patients and controls (*P*=0.036), though the difference was lost after Bonferroni correction. Compared with the AA genotype, the AG + GG genotype reduced the disease risk (OR~AG\ +\ GG~ 0.358, 95% CI~AG\ +\ GG~ 0.151--0.851). In addition, a lower risk of paranoid schizophrenia was associated with the AG + GG genotype of rs4532 (OR~AG\ +\ GG~ 0.592, 95% CI~AG\ +\ GG~ 0.350--1.001) compared with the AA genotype. No remaining loci exhibited significant differences in allele or genotype frequencies between the patients and controls.

A comparison of the frequencies of haplotypes formed by the seven SNPs in the block was analyzed between the patients and controls. The results are shown in [Table 2](#t2-ndt-10-645){ref-type="table"}. The remaining four SNPs outside the block formed the haplotypes, and the result is shown in [Table 3](#t3-ndt-10-645){ref-type="table"}. All-haplotype analysis found that there was no association with the occurrence of paranoid schizophrenia between patients and controls.

A study reported that sexually dimorphic *DRD1* SNPs impacted on the risk of schizophrenia.[@b19-ndt-10-645] Therefore, we stratified the observed association of rs5326 and rs4532 with the risk of paranoid schizophrenia based on sex by the *χ*^2^ test (results shown in [Table 4](#t4-ndt-10-645){ref-type="table"}). In males, the genotype distribution of rs5326 was statistically different between cases and controls (*P*=0.048). In females, the genotype distribution of rs4532 was statistically different between cases and controls (*P*=0.029). However, these significant differences disappeared after Bonferroni correction.

Discussion
==========

In the present study, we investigated eleven SNPs in the *DRD1* gene in a northern Chinese Han population by DNA sequencing. There were no significant differences in allele, genotype, or haplotype frequencies between paranoid schizophrenia patients and controls after Bonferroni correction. Consistent with our results, some studies reported no significant association between the *DRD1* gene and schizophrenia.[@b20-ndt-10-645],[@b23-ndt-10-645] However, several previous studies have reported that the *DRD1* gene is associated with bipolar disorder,[@b21-ndt-10-645] attention deficit with hyperactivity disorders,[@b24-ndt-10-645] nicotine dependence,[@b25-ndt-10-645] alcohol dependence,[@b26-ndt-10-645] and others. Compared with these diseases, schizophrenic patients have the same or similar symptoms.

Our results found that the AG + GG genotype of rs5326, as a protective factor for schizophrenia, could reduce the risk of paranoid schizophrenia, as assessed by the *χ*^2^ test. Zhu et al[@b27-ndt-10-645] reported that rs5326 was not associated with schizophrenia in the Chinese Han population, which was consistent with previous studies.[@b28-ndt-10-645],[@b29-ndt-10-645] The interaction between the *DNMT3B* and *DRD1* genes significantly increased the risk of schizophrenia after analysis with multifactor dimensionality reduction software.[@b29-ndt-10-645] This also shows that the incidence of schizophrenia is affected by the interaction of multiple genes, and studies of only one gene cannot clearly explain the pathogenesis. Although some studies[@b20-ndt-10-645],[@b26-ndt-10-645],[@b30-ndt-10-645] found no association between rs4532 and schizophrenia, a meta-analysis[@b31-ndt-10-645] indicated that *DRD1* might contain a genuine susceptibility allele, and the OR of rs4532 reached 1.18 (95% CI 1.01--1.38). In addition, rs4532 was associated with antipsychotic treatment in schizophrenia[@b32-ndt-10-645],[@b33-ndt-10-645] and working memory and cognitive behavior related to the prefrontal cortex.[@b6-ndt-10-645],[@b13-ndt-10-645] This shows that rs4532 likely has a potential link with the etiology of schizophrenia. Furthermore, the inconsistency of association studied between *DRD1* and schizophrenia may result from genetic heterogeneity, which is an important challenge in the genetic study of schizophrenia. In our study, we reported rs201089398 for the first time. However, this new locus had a slightly lower frequency, and we failed to reveal its potential association with schizophrenia in the Chinese Han population.

The pathogenesis of schizophrenia is the participation of a variety of risk factors, and sex is an important factor.[@b34-ndt-10-645],[@b35-ndt-10-645] Our study showed that rs5326 was statistically different between cases and controls in males and rs4532 was statistically different between cases and controls in females by the *χ*^2^ test. Unfortunately, the impact of sex-specific mechanisms in schizophrenia is unclear, and needs further exploration in the future. In addition, there was another limitation in our study in that we did not analyze positive and negative symptoms or cognitive performance of the patients, owing to the lack of original information.

What can we learn from these results? First, the analysis of just one gene is far from enough, because *DRD1* may result in schizophrenia by interacting with other dopaminergic-related genes, such as synthase genes, metabolic genes, transporter genes, and others. Additionally, other neurotransmitters are also involved in the pathogenesis of schizophrenia. We cannot definitively rule out a role for any of these genes in schizophrenia. Therefore, further studies should be focused on genome-wide SNP analysis and gene--gene interactions to determine their possible roles in the etiology of schizophrenia.

Second, multiethnic studies with large samples are essential. Many of the ORs for association are in a plausible range (1.10--1.23) for small susceptibility effects, but below what would produce significant *P*-values in smaller samples.[@b36-ndt-10-645] The larger ORs in some previous reports may either be false positives or inflated estimates of genetic effects, while association studies of large samples provide more power. In the present study, we reported rs201089398 for the first time. With regard to the limited samples, the slightly lower frequency of this new locus might not reveal the potential association with schizophrenia in the Chinese Han population. Besides, our results demonstrated that the genotype frequencies of *DRD1* are variable in different ethnic groups. Therefore, through multiethnic studies, it will likely be easier to find a genetic effect for susceptibility to schizophrenia.

Third, genetic heterogeneity is a significant challenge in the study of schizophrenia,[@b37-ndt-10-645] and family-based studies could overcome this problem effectively.[@b38-ndt-10-645] Our results need to be clarified through analysis of extensive family studies. Additionally, paranoid schizophrenia, as a subtype of schizophrenia, includes positive and negative symptoms, which show different clinical manifestations. Unfortunately, due to the limited data, we did not do a more detailed analysis. Overall, the shortcomings of our study could partially inform future researchers.

In summary, although our study did not find a genetic association between *DRD1* and paranoid schizophrenia, its possible role in the risk of schizophrenia cannot be definitively excluded. Further and larger studies are necessary to evaluate the effect of *DRD1* polymorphisms on the etiology of schizophrenia, and our data may provide a reference.

Special thanks to the Third People's Hospital of Liaoning Province for providing blood samples from paranoid schizophrenic patients for this experiment.
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![Schematic diagram of the distribution of eleven SNP loci in the *DRD1* gene.\
**Abbreviations:** CDS, coding sequence; SNP, single nucleotide polymorphism; ATG, transcription start site; STOP, stop codon.](ndt-10-645Fig1){#f1-ndt-10-645}

![Linkage-disequilibrium diagram of eleven single-nucleotide polymorphism loci in *DRD1*. The top row represents the disease group, while the bottom shows the control group; the left is *r*^2^, and the right is D′. The black grid represents *r*^2^=1; the blank grid represents D′=1.](ndt-10-645Fig2){#f2-ndt-10-645}

###### 

Distribution of genotype frequencies, allele frequencies, and disease risk at the eleven SNP loci in *DRD1* for the control and disease groups

  Variable          Cases (n=173)   Control (n=213)   *P*-value[a](#tfn1-ndt-10-645){ref-type="table-fn"}   OR, 95% CI           
  ----------------- --------------- ----------------- ----------------------------------------------------- ------------ ------- ---------------------
  **rs267410**                                                                                                           0.328   
  AA                43              24.9              59                                                    27.7                 1
  AC                69              39.9              94                                                    44.1                 1.007, 0.610--1.662
  CC                61              35.3              60                                                    28.2                 1.395, 0.821--2.371
  AC + CC           130             75.2              154                                                   72.3         0.529   1.158, 0.733--1.829
  Per C allele      191             55.2              214                                                   50.2         0.169   1.221, 0.918--1.623
  **rs10078866**                                                                                                         0.984   
  AA                97              56.1              120                                                   56.3                 1
  AG                63              36.4              78                                                    36.6                 0.999, 0.652--1.531
  GG                13              7.5               15                                                    7.0                  1.072, 0.487--2.361
  AG + GG           76              43.9              93                                                    43.6         0.958   1.011, 0.675--1.515
  Per G allele      89              73.6              108                                                   69.8         0.907   1.020, 0.737--1.412
  **rs10063995**                                                                                                         0.157   
  GG                95              54.9              118                                                   55.4                 1
  GT                73              42.2              80                                                    37.6                 1.133, 0.747--1.719
  TT                5               2.9               15                                                    7.0                  0.414, 0.145--1.180
  GT + TT           78              45.1              95                                                    44.6         0.924   1.020, 0.681--1.526
  Per T allele      83              24.0              110                                                   25.8         0.559   0.907, 0.653--1.259
  **rs10078714**                                                                                                         0.899   
  AA                99              57.2              119                                                   55.9                 1
  AG                63              36.4              78                                                    36.6                 0.971, 0.634--1.486
  GG                11              6.4               16                                                    7.5                  0.826, 0.367--1.863
  AG + GG           74              42.8              94                                                    44.1         0.789   0.946, 0.631--1.418
  Per G allele      85              24.6              110                                                   25.8         0.690   0.936, 0.675--1.298
  **rs146439723**                                                                                                        0.374   
  AA                0               0.0               0                                                     0.0                  1
  AG                12              6.9               8                                                     3.8                  1.910, 0.763--4.783
  GG                161             93.1              205                                                   96.2                 --
  AG + GG           173             100.0             213                                                   100.0        --      --
  Per G allele      334             96.5              418                                                   98.1         0.167   0.533, 0.215--1.318
  **rs35916350**                                                                                                         0.265   
  CC                2               1.2               0                                                     0.0                  1
  CG                20              11.6              28                                                    13.1                 --
  GG                151             87.3              185                                                   86.9                 --
  CG + GG           171             98.9              213                                                   100.0        0.116   --
  Per G allele      322             93.1              398                                                   93.4         0.841   0.944, 0.537--1.660
  **rs201089398**                                                                                                        0.632   
  TT                159             91.9              201                                                   94.4                 1
  TC                14              8.1               12                                                    5.6                  1.475, 0.664--3.278
  CC                0               0.0               0                                                     0.0                  --
  TC + CC           14              8.1               12                                                    5.6          0.338   1.475, 0.664--3.278
  Per C allele      14              4.0               12                                                    2.8          0.346   1.455, 0.664--3.188
  **rs265981**                                                                                                           0.074   
  AA                1               0.6               0                                                     0.0                  1
  AG                25              14.5              48                                                    22.5                 --
  GG                147             85.0              165                                                   77.5                 --
  AG + GG           172             99.5              213                                                   100.0        0.267   --
  Per G allele      319             92.2              378                                                   88.7         0.106   1.500, 0.915--2.460
  **rs193082222**                                                                                                        0.995   
  AA                0               0.0               0                                                     0.0                  1
  AC                6               3.5               7                                                     3.3                  1.057, 0.349--3.206
  CC                167             96.5              206                                                   96.7                 --
  AC + CC           173             100.0             213                                                   100.0        1.000   --
  Per C allele      340             98.3              419                                                   98.4         0.992   0.947, 0.315--2.843
  **rs5326**                                                                                                             0.036   
  AA                17              9.8               8                                                     3.8                  1
  AG                64              37.0              94                                                    44.1                 0.320, 0.130--0.787
  GG                92              53.2              111                                                   52.1                 0.390, 0.161--0.945
  AG + GG           156             90.2              205                                                   96.2         0.016   0.358, 0.151--0.851
  Per G allele      248             71.7              316                                                   74.2         0.436   0.881, 0.640--1.212
  **rs4532**                                                                                                             0.060   
  TT                147             85.0              164                                                   77.0                 1
  TC                25              14.5              49                                                    23.0                 0.569, 0.335--0.968
  CC                1               0.6               0                                                     0.0                  --
  TC + CC           26              15.1              49                                                    23.0         0.049   0.592, 0.350--1.001
  Per C allele      27              7.8               49                                                    11.5         0.086   1.536, 0.938--2.514

**Notes:**

*P*-values calculated by 2×3 and 2×2 *χ*^2^ tests (for codominant, dominant for minor allele, and allele model), with *P*\<0.05 statistically significant. Due to the small number of genotypes of several SNPs or missing data, statistical values that could not be calculated are represented by solo en dashes.

**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Haplotypes formed by the seven SNP loci in *DRD1* and disease risk

  --------------------------------------------------------------------------------------------------------------------------------
  Haplotype   SNP   Cases\    Controls\   *P*-value   OR, 95% CI                                             
                    (n=346)   (n=426)                                                                        
  ----------- ----- --------- ----------- ----------- ------------ --- --- ----- ------ ----- ------ ------- ---------------------
  1           A     G         G           C           T            G   C   197   56.9   241   56.5   0.919   1.015, 0.762--1.351

  2           A     A         G           C           T            G   C   67    19.4   84    19.7   0.902   0.978, 0.684--1.398

  3           G     G         G           T           T            G   C   26    7.6    48    11.3   0.078   0.640, 0.388--1.055

  4           A     A         G           C           T            C   C   24    6.9    26    6.0    0.640   1.147, 0.646--2.036
  --------------------------------------------------------------------------------------------------------------------------------

**Note:** Haplotype with frequency \<0.05 were excluded.

**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Haplotypes formed by the remaining four SNP loci in *DRD1* and disease risk

  ------------------------------------------------------------------------------------------------------------------
  Haplotype   SNP   Cases\    Controls\   *P*-value   OR, 95% CI                               
                    (n=346)   (n=426)                                                          
  ----------- ----- --------- ----------- ----------- ------------ ------ ----- ------ ------- ---------------------
  1           T     C         T           T           163          47.2   177   41.5   0.122   1.253, 0.942--1.668

  2           T     C         T           G           80           23.2   120   28.2   0.111   0.767, 0.553--1.064

  3           C     A         C           G           69           19.9   91    21.4   0.629   0.917, 0.646--1.303
  ------------------------------------------------------------------------------------------------------------------

**Note:** Haplotype with frequency \<0.05 were excluded.

**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Distribution of genotype frequency and disease risk at two SNP loci in *DRD1* for sex in control and disease groups

  Variable   rs5326 (cases/controls)   *P*-value   OR, 95% CI   rs4532 (cases/controls)   *P*-value   OR, 95% CI           
  ---------- ------------------------- ----------- ------------ ------------------------- ----------- ------------ ------- ---------------------
  Male       8/3                       80/109      0.048        0.275, 0.071--1.070       73/89       15/23        0.532   0.795, 0.387--1.634
  Female     9/5                       76/96       0.147        0.440, 0.142--1.367       74/75       11/26        0.029   0.429, 0.198--0.930

**Abbreviations:** SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
